Will BMA (British Medical Association) fireworks throw light on medtech-hitting reforms?
This article was originally published in Clinica
The annual representative meeting of the British Medical Association (BMA), which got underway today in Belfast, will air deep misgivings over healthcare reforms that impinge on the medical technology industry's position at the sharp end of cost-cutting measures.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.